Relatlimab + nivolumab: a potential new combination in first-line advanced melanoma
In this MEDtalk, Marco Donia, Center for Cancer Immune Therapy, Herlev Hospital, Denmark, gives his perspective of the data from RELATIVITY-047 presented by Evan J. Lipson during ASCO Virtual 2021.